MedTrace Logo

Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry

NCT02663076 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1700

Last updated 2022-07-19

No results posted yet for this study

Summary

The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2).

The overall objective of this registry is to assess chronic kidney disease (CKD) progression and clinical outcomes with regard to anticoagulation strategies in NVAF patients with eGFR 15-49 mL/min per 1.73 m2 in routine clinical practice.

Conditions

  • Non-valvular Atrial Fibrillation (NVAF)
  • Chronic Kidney Disease (CKD)

Sponsors & Collaborators

  • ClinStat GmbH

    collaborator UNKNOWN

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Reinhold Kreutz, Prof. Dr. · Charite University, Berlin, Germany

  • Jan Beyer-Westendorf, PD Dr. · University Clinic Technical University Dresden

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2022-01-31
Completion
2022-04-04

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02663076 on ClinicalTrials.gov